The University of Manchester
The University of Manchester is a global leader in early detection, combining clinical excellence and community research to address hereditary cancers, immunology and health inequalities.
About the centre
A member since our launch in 2019, the International Alliance for Cancer Early Detection (ACED) centre at The University of Manchester co-leads the inherited cancers, cancer inequalities and immunology research themes, focusing on T cell receptor-based detection. Its community-led research, such as the BCAN-RAY study, exemplifies the centre's commitment to tackling inequalities by bringing screening and research into underserved community settings.
This centre is part of the Manchester Cancer Research Centre (MCRC) partnership. The MCRC integrates The University of Manchester, The Christie NHS Foundation Trust and the Cancer Research UK Manchester Institute. It also hosts the National Biomarker Centre and provides unique access to rare hereditary cohorts and the relocated UK Biobank.
The ACED centre in Manchester plays a key role in training the next generation of early detection researchers through the ACED network, facilitating skills exchanges and supporting funded PhD students and postdoctoral fellows.
Learn more about The University of ManchesterCore expertise and resources
National Biomarker Centre for large-scale biomarker discovery and validation
rare hereditary cohorts including Lynch syndrome, Li-Fraumeni and BRCA1/2 populations
hosts ACED-funded PhD students and skills exchange opportunities
community engagement and co-designed trials, including BCAN-RAY study
Key contacts
Robert Bristow
The University of Manchester ACED Centre Director
Emma Woodward
The University of Manchester ACED Centre Deputy Director
Martin Bone
The University of Manchester ACED Centre Programme Manager